Literature DB >> 20458329

Immunologic mechanisms in RCC and allogeneic renal transplant rejection.

Jens Bedke1, Arnulf Stenzl.   

Abstract

The tolerance state that exists between renal cell carcinoma (RCC) and the host's immune system would be an ideal situation in the setting of human kidney transplantation, in which graft tolerance is the ultimate goal of immunosuppressive therapy. On the other hand, acute rejection, as it appears in renal allografts, would be the optimal immunologic situation in patients with RCC. Analysis of the underlying mechanisms of acute allograft rejection and local pro-tumor immunosuppression could help to identify potential therapeutic targets for inducing immune tolerance in allograft recipients and immune rejection in RCC patients. Experimental kidney transplantation might be a suitable model in which to analyze these processes. Macrophages are a prominent and vital cell type in the cellular infiltrate seen in both RCC and renal allografts. Depending on their polarization, they can initiate and promote either proinflammatory or pro-tumor responses, which lead to tissue rejection or acceptance, respectively. Improved understanding of macrophage biology could lead to therapeutic modification of their function in order to promote a desirable immunologic response in either RCC or transplant tissue.

Entities:  

Mesh:

Year:  2010        PMID: 20458329     DOI: 10.1038/nrurol.2010.59

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  96 in total

1.  A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).

Authors:  Subhra K Biswas; Lisa Gangi; Saki Paul; Tiziana Schioppa; Alessandra Saccani; Marina Sironi; Barbara Bottazzi; Andrea Doni; Bronte Vincenzo; Fabio Pasqualini; Luca Vago; Manuela Nebuloni; Alberto Mantovani; Antonio Sica
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

2.  IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo.

Authors:  Stephanie K Watkins; Nejat K Egilmez; Jill Suttles; Robert D Stout
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage.

Authors:  Jens Bedke; Peter J Nelson; Eva Kiss; Niklas Muenchmeier; Angelika Rek; Carl-Ludwig Behnes; Norbert Gretz; Andreas J Kungl; Hermann-Josef Gröne
Journal:  Mol Immunol       Date:  2009-12-11       Impact factor: 4.407

Review 5.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

6.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 7.  Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.

Authors:  Steven J O'Day; Omid Hamid; Walter J Urba
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

Review 8.  25 years of UV-induced immunosuppression mediated by T cells-from disregarded T suppressor cells to highly respected regulatory T cells.

Authors:  Thomas Schwarz
Journal:  Photochem Photobiol       Date:  2008 Jan-Feb       Impact factor: 3.421

Review 9.  Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.

Authors:  Robert J Kreitman
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.

Authors:  Sergei Kusmartsev; Zhen Su; Axel Heiser; Jens Dannull; Evgeniy Eruslanov; Hubert Kübler; Donna Yancey; Philip Dahm; Johannes Vieweg
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

View more
  5 in total

Review 1.  [Prostate carcinoma: vaccination as a new option for treatment].

Authors:  J Bedke; C Gouttefangeas; A Stenzl
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

2.  [Renal cell carcinoma: recent developments in diagnostics and therapy].

Authors:  J Bedke; A Stenzl
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

3.  Red cell distribution width is associated with presence, stage, and grade in patients with renal cell carcinoma.

Authors:  Fang-Ming Wang; Gongjun Xu; Yan Zhang; Lu-Lin Ma
Journal:  Dis Markers       Date:  2014-12-16       Impact factor: 3.434

4.  Dramatic early event in chronic allograft nephropathy: increased but not decreased expression of MMP-9 gene.

Authors:  Dongfeng Gu; Yanling Shi; Yanan Ding; Xinyu Liu; Hequn Zou
Journal:  Diagn Pathol       Date:  2013-01-28       Impact factor: 2.644

5.  Profiling the Resident and Infiltrating Monocyte/Macrophages during Rejection following Kidney Transplantation.

Authors:  Jie Wang; Peiling Luo; Jingjie Zhao; Junhua Tan; Feifan Huang; Ruiying Ma; Peng Huang; Meiying Huang; Yuming Huang; Qiuju Wei; Liuzhi Wei; Zechen Wang; Lingzhang Meng
Journal:  J Immunol Res       Date:  2020-09-21       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.